Splenic marginal zone lymphoma is a rare, indolent B-cell non-Hodgkin lymphoma characterized by abnormal clonal proliferation of mature B-lymphocytes with involvement in the spleen, bone marrow and, f...
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
The limited documentation surrounding splenic marginal zone lymphoma is largely due to its rarity, affecting fewer than 10 individuals per million. This extreme rarity restricts the ability to conduct systematic clinical studies, leading to gaps in our understanding of its genetic basis and clinical features. Additionally, the overlap of symptoms with other conditions complicates the characterization of SMZL, making it a challenging area for research.
To navigate your care for splenic marginal zone lymphoma, consider seeking a hematologist or oncologist with expertise in lymphomas, particularly B-cell non-Hodgkin lymphomas. You may also explore participation in clinical trials, which can provide access to novel therapies. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer support and information. While no specific patient organizations are currently identified, engaging with clinical trial networks might provide additional resources and community support.
Currently, there are several FDA-approved treatments for splenic marginal zone lymphoma, including ibrutinib, lenalidomide, lisocabtagene maraleucel, umbralisib, and zanubrutinib. Additionally, there are designated orphan drugs in development such as idelalisib, odronextamab, parsaclisib, and tafasitamab-cxix. There are also 17 active clinical trials focused on this condition. For more information on these trials, you can visit the ClinicalTrials.gov search page at https://clinicaltrials.gov/search?cond=splenic%20marginal%20zone%20lymphoma.
Actionable guidance for navigating care for splenic marginal zone lymphoma
To navigate your care for splenic marginal zone lymphoma, consider seeking a hematologist or oncologist with expertise in lymphomas, particularly B-cell non-Hodgkin lymphomas. You may also explore participation in clinical trials, which can provide access to novel therapies. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer support and information. While no specific patient organizations are currently identified, engaging with clinical trial networks might provide additional resources and community support.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 11 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning splenic marginal zone lymphoma
Updated Dec 4, 2025
FDA approves Breyanzi (lisocabtagene maraleucel) as the first CAR T-cell therapy for marginal zone lymphoma in the U.S. This approval marks a significant advancement in treatment options for patients with this rare blood cancer.